Unmasking of schizophrenia following COVID vaccination

Grover, Sandeep; Laxmi, Raj

doi:10.4103/indianjpsychiatry.indianjpsychiatry_607_22

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there have been concerns about worsening schizophrenia symptoms after vaccination. 23 , 24 Some studies have suggested increased depression and anxiety experienced by schizophrenia patients after vaccinations. 5 Nonetheless, this might be associated with vaccination behavior and psychological distress to the rapid approval of COVID-19 vaccinations during the pandemic that raised concerns and vaccination hesitancy rather than the vaccine itself.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Dyu,

Leung,

Simões-e-Silva

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

ChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database in Brazil. Individuals diagnosed with COVID-19 and schizophrenia were included in the study. The exposures were 0, 1, and 2 doses of ChAdOx1-S. The outcome of mortality was measured in hazard ratios (HR), calculated using multivariable Cox regression models. The study included 1,929 positive cases of COVID-19 in schizophrenia patients. After adjusting for age, socioeconomic factors, and comorbidities, we observed a significant 55% decrease in the hazard of mortality in the 2-dose vaccination group (HR 0.45, 95% CI: 0.310–0.652) compared to the unvaccinated. Surprisingly, our results did not show any significant reduction in the hazard of mortality in the 1 dose vaccination group (HR 1.278, 95% CI: 0.910–1.795). The effectiveness of two doses of ChAdOx1-S in individuals with schizophrenia aligns with findings from studies on the general population. That one dose was insignificant. Overall, these findings are important for informing public health decisions – prioritizing individuals with schizophrenia for vaccinations and managing acceptance of vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Dyu,

Leung,

Simões-e-Silva

2024

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

Aripiprazole/AZD-1222/olanzapine

2023

Reactions Weekly

View full text Add to dashboard Cite

New-onset psychosis following COVID-19 vaccination: a systematic review

Lazareva,

Renemane,

Vrublevska

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

BackgroundThe emergence of a new coronavirus strain caused the COVID-19 pandemic. While vaccines effectively control the infection, it’s important to acknowledge the potential for side effects, including rare cases like psychosis, which may increase with the rising number of vaccinations.ObjectivesOur systematic review aimed to examine cases of new-onset psychosis following COVID-19 vaccination.MethodsWe conducted a systematic review of case reports and case series on new-onset psychosis following COVID-19 vaccination from December 1st, 2019, to November 21st, 2023, using PubMed, MEDLINE, ClinicalKey, and ScienceDirect. Data extraction covered study and participant characteristics, comorbidities, COVID-19 vaccine details, and clinical features. The Joanna Briggs Institute quality assessment tools were employed for included studies, revealing no significant publication bias.ResultsA total of 21 articles described 24 cases of new-onset psychotic symptoms following COVID-19 vaccination. Of these cases, 54.2% were female, with a mean age of 33.71 ± 12.02 years. Psychiatric events were potentially induced by the mRNA BNT162b2 vaccine in 33.3% of cases, and psychotic symptoms appeared in 25% following the viral vector ChAdOx1 nCoV-19 vaccine. The mean onset time was 5.75 ± 8.14 days, mostly reported after the first or second dose. The duration of psychotic symptoms ranged between 1 and 2 months with a mean of 52.48 ± 60.07 days. Blood test abnormalities were noted in 50% of cases, mainly mild to moderate leukocytosis and elevated C-reactive protein. Magnetic resonance imaging results were abnormal in 20.8%, often showing fluid-attenuated inversion recovery hyperintensity in the white matter. Treatment included atypical antipsychotics in 83.3% of cases, typical antipsychotics in 37.5%, benzodiazepines in 50%, 20.8% received steroids, and 25% were prescribed antiepileptic medications. Overall, 50% of patients achieved full recovery.ConclusionStudies on psychiatric side effects post-COVID-19 vaccination are limited, and making conclusions on vaccine advantages or disadvantages is challenging. Vaccination is generally safe, but data suggest a potential link between young age, mRNA, and viral vector vaccines with new-onset psychosis within 7 days post-vaccination. Collecting data on vaccine-related psychiatric effects is crucial for prevention, and an algorithm for monitoring and treating mental health reactions post-vaccination is necessary for comprehensive management.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO, identifier CRD42023446270.

show abstract

Unmasking of schizophrenia following COVID vaccination

Cited by 3 publications

References 4 publications

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study

Aripiprazole/AZD-1222/olanzapine

New-onset psychosis following COVID-19 vaccination: a systematic review

Contact Info

Product

Resources

About